Journal updates

Guest Editors:

Diana A Gorog, National Heart and Lung Institute, Imperial College, London, UK
Geoffrey D Barnes,  University of Michigan Health, USA

Antithrombotic medications remain the cornerstone in the management of cardiovascular disease. While currently available medications greatly reduce ischemic and thromboembolic risk in a number of conditions, ranging from venous thromboembolism to coronary artery disease, myocardial infarction and stroke, these agents have limitations. These include a residual ischemic risk despite current optimal medications in some individuals, delayed onset of action in others, whilst yet others may experience bleeding complications. These factors contribute significantly to mortality and morbidity.

Currently, there are several novel antithrombotic medications on the horizon, undergoing clinical and/or laboratory evaluation. These include, among others, intravenous and subcutaneous antiplatelet medications, and novel anticoagulants including those targeting factor XI and factor XII.

We are launching a call for papers for a special themed issue of the Journal of Thrombosis and Thrombolysis on “Novel Antithrombotic Medications” to highlight research in this important emerging field. Submission may take the form of original research (clinical, translational or basic science), clinical trials, meta-analyses, or review articles.

Please indicate in a cover letter if your submission is targeted at this call.

Submit your manuscript here (this opens in a new tab)

Please see the submission guidelines here (this opens in a new tab)